DOCSLIB.ORG

FREQUENCY of SUBMITTING Periodic Safety Update Reports for Medicinal Products, Vaccines, Tuberculin* by INN of API Or Combination of API

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FREQUENCY of SUBMITTING Periodic Safety Update Reports for Medicinal Products, Vaccines, Tuberculin* by INN of API Or Combination of API Annex 10 of Pharmacovigilance Procedure (subitem 2 of item 3 of chapter 1 of section VI) FREQUENCY OF SUBMITTING periodic safety update reports for medicinal products, vaccines, tuberculin* by INN of API or combination of API INN of API or combination of API PSUR Data lock Submission Publication submission point date date frequency 1 2 3 4 5 125i-human serum albumin 13 years 15/12/2025 15/03/2026 5 fluorouracil (i.v. application) 3 years 16/12/2017 16/03/2018 5-aminolevulinic acid (glioma) 3 years 07/03/2018 05/06/2018 5-aminolevulinic acid (keratosis) 1 year 14/06/2018 23/08/2018 abacavir 3 years 31/12/2019 31/03/2020 abacavir, lamivudine 3 years 31/12/2019 31/03/2020 abacavir, lamivudine, zidovudine 3 years 31/12/2019 31/03/2020 abies oil, camphor, salicylic acid, venom viper 13 years 31/12/2018 31/03/2019 abies oil, dauci sativi fluidum, origani fluidum, 13 years 31/12/2018 31/03/2019 peppermint oil, strobili lupuli fluidum abiraterone 1 year 27/04/2018 06/07/2018 abrus precatorius, acacia catechu, adhatoda 13 years 31/12/2018 31/03/2019 vasica, alpinia galanga, curcuma, emblica oficinale, foeniculum, glycyrrhiza, menthol, ocimum sanctum, piper longum, piper nigrum, terminalia chebula, terminalia belerica, zingiber officinale abrus precatorius, aconitum napellus, 13 years 31/12/2018 31/03/2019 belladonna, calendula, chelidonium majus, viburnum opulus absinthii, achillea, althaea, calami, calendula, 5 years 31/12/2018 31/03/2019 glycyrrhiza, helichrysum arenarium, hypericum, matricaria, mentha piperita, salvia officinalis, sambucus, sophora japonica, rosa, urtica absinthii, achillea, anethi, calami, leuzeae 13 years 31/12/2018 31/03/2019 carthamoide, menthae piperitae, menyanthidis, tiliae, quercus absinthii, angelicae, anserinae, cnici ben, 5 years 31/12/2018 31/03/2019 glycyrrhiza, hypericum, matricariae absinthii, calami rhizomata, helishrysi arenarii, 5 years 31/12/2018 31/03/2019 hypericum, menthae piperitae, quercus cortex, potentilla, taraxaci radices, zeae maydis styli cum stigmatis acacia arabica, aegle marmelos, anacyclus 5 years 31/12/2018 31/03/2019 pyrethrum, argyreia speciosa, asparagus racemosus, bombax malabaricum, clerodendrum phlomidis, crocus sativus, dashamoola stereospermum suaveolens, desmodium gangenticum gmeline arborea, hibiscus abelmoschus, hydrargyrum sulfidum ruber, ipomoea digitata, minerale pix purum, mucuna pruriens, orchis mascula, oroxylum indicum, plumbum, sida cordifolia, solanum anguivi, solanium xanthocarpum stannum, strychnos nux-vomica, piper betle, piper nigrum, tinospora cordifolia, tribulus terrestris, uraria picta, withania somnifera, zincum acarbose 3 years 31/03/2018 29/06/2018 aceclofenac 3 years 31/03/2020 29/06/2020 acenocoumarol 9 years 01/07/2021 29/09/2021 acetazolamide 16 years 01/01/2028 31/03/2028 acetic acid, amylmetacresolum, sodium 13 years 31/12/2018 31/03/2019 ascorbate, spiritus dichlorobenzylicus acetic acid, azotic acid, oxalic acid dyhydrat, 13 years 31/12/2018 31/03/2019 zink nitrate acetone, boric acid, fuchsin, phenol, resorcin 13 years 01/01/2025 01/04/2025 acetylaminonitropropoxybenzene (falimint) 5 years 01/01/2020 31/03/2020 acetylated wool alcohols, liquid paraffin 13 years 01/01/2025 01/04/2025 acetylcysteine 3 years 13/09/2018 12/12/2018 acetylcysteine, ambroxol 3 years 13/02/2020 14/05/2020 acetylcysteine, acetyl tyrosine, calcium chloride, 13 years 01/01/2025 01/04/2025 glycine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-isoleucine, L- leucine, L-malic acid, L-methionine, L- phenylalanine, L-proline, L-serine, L-valine, L- threonine, L-tryptophan, lysine acetate, magnesium chloride, ornithine hydrochloride, potassium chloride, sodium acetate, sodium hydroxide, sodium chloride acetylcysteine, tuaminoheptan sulfate 13 years 01/03/2025 30/05/2025 acetylsalicylic acid 3 years 01/02/2019 02/05/2019 acetylsalicylic acid, aminoacetic acid 3 years 01/02/2019 02/05/2019 acetylsalicylic acid, ascorbic acid 23 years 04/02/2035 05/05/2035 acetylsalicylic acid, bisoprolol 3 years 05/11/2018 13/02/2019 acetylsalicylic acid, caffeine, paracetamol 13 years 24/10/2025 22/01/2026 acetylsalicylic acid, chlorphenamine, 13 years 01/01/2025 01/04/2025 phenylephrine acetylsalicylic acid, citric acid, sodium hydrogen 13 years 01/01/2025 01/04/2025 carbonate acetylsalicylic acid, clopidogrel / clopidogrel 3 years 17/11/2019 15/02/2020 acetylsalicylic acid, dipyridamole 13 years 05/04/2025 04/07/2025 acetylsalicylic acid, glycine 18 years 01/01/2030 01/04/2030 acetylsalicylic acid, magnesium hydroxide 13 years 01/01/2025 01/04/2025 achillea 13 years 31/12/2018 31/03/2019 achillea, aconitum napellus, arnica montana, 13 years 31/12/2018 31/03/2019 atropa belladonna, bellis perennis, calendula officinalis, echinacea, echinacea purpurea, hamamelis virginiana, hepar sulfuris, hypericum perforatum, matricaria recutita, mercurius solubilis hahnemanni, symphytum achillea, acorus calamus, anethum graveolens, 13 years 31/12/2018 31/03/2019 artemisia, mentha piperita, menyanthes trifoliata, quercus robur, rhaponticum carthamoides, tilia cordata achillea, acorus, calendula, capsella bursa- 5 years 31/12/2018 31/03/2019 pastoris, chamomilla, chelidonium, hypericum, origanum, vinca minor achillea, althaea, equisetum, juglans regia, 13 years 31/12/2018 31/03/2019 matricaria, quercus, taraxacum achillea, arctostaphylos, betula, ononis spinosa, 13 years 31/12/2018 31/03/2019 petroselinum, polygonum, sambucus nigra, urtica achillea, belladonnae, benzocaine, cytisus 13 years 31/12/2018 31/03/2019 scoparium, hippocastani corticis, matricariae extractum spissum, tormentilla achillea, boerhaavia diffusa, capparis spinosa, 13 years 31/12/2018 31/03/2019 cassia occidentalis, cichorium intybus, eclipta alba, embelia ribes, emblica officinalis, fumaria officinalis, mandur bhasma, phyllanthus amarus, plumbago zeylanica, raphanus sativus, solanum nigrum, tamarix gallica, terminalia arjuna, terminalia chebula, tinospora cordifolia achillea, calendula, clotrimazole, gentamicine 13 years 28/02/2020 28/05/2020 achillea, calendula, crataegus, hypericum, 5 years 31/12/2018 31/03/2019 matricaria, polygonum, rosa achillea, calendula, crataegus, humulus lupulus, 13 years 31/12/2018 31/03/2019 linum, matricaria, mentha piperita, plantago major achillea, calendula, hypericum, mentha, 5 years 31/12/2018 31/03/2019 plantago, sambucus, tussilago achillea, calendula, hypericus, matricaria, 13 years 31/12/2018 31/03/2019 menthae piperitae achillea, calendula, matricaria 13 years 31/12/2018 31/03/2019 achillea, calendula, chelidonium, matricaria, 13 years 31/12/2018 31/03/2019 mentha piperita, tanacetum achillea, calendula, chelidonium, lavandula, 13 years 31/12/2018 31/03/2019 matricaria, mentha piperita, tanacetum achillea, calendula, lavandula, matricaria, 13 years 31/12/2018 31/03/2019 mentha piperita, tanacetum achillea, calendulae, hypericum, matricariae, 5 years 31/12/2018 31/03/2019 menthae piperitae achillea, carophylenum, propolis, sophora 13 years 31/12/2018 31/03/2019 japonica, potentilla achillea, coriandrum, helichrysum arenarium, 13 years 31/12/2018 31/03/2019 mentha piperita achillea, crataegus, humulus lupulus, mentha 13 years 31/12/2018 31/03/2019 piperita, valeriana achillea, lycium cortice, urtica foliis 13 years 31/12/2018 31/03/2019 achyranthes aspera, cyperus scariosus, 13 years 31/12/2018 31/03/2019 didymocarpus pedicellata, dolichos biflorus, equisetum arvense, hajrul yahood bhasma, mimosa pudica, ocimum basilicum, onosma bracteatum, pavonia odorata, rubia cordifolia, saxifraga ligulata, shilajeet purified, tectona grandis seed, tribulus terrestris, vernonia cinerea aciclovir 3 years 09/06/2018 07/09/2018 aciclovir, hydrocortisone 3 years 30/07/2020 28/10/2020 aciclovir, interferon alfa-2b, lidocaine 3 years 09/06/2018 07/09/2018 acid citric, adenine, dextrose monohydrate, 13 years 30/05/2020 28/08/2020 sodium citrate, sodium dihydrogen phosphate acid citric, adenine, glucose monohydrate, 13 years 30/05/2020 28/08/2020 mannitol, sodium citrate, sodium chloride, sodium dihydrogen phosphate acidum acetylsalicylicum, acidum alpha- 13 years 31/12/2018 31/03/2019 liponicum, acidum ascorbicum, acidum sarcolacticum, adenosinum triphosphoricum, anthrachinonum, coenzym, colchicum autumnale, conium maculatum, galium aparine, histaminum, hydrastis canadensis, hydrochinonum, magnesium gluconicum, manganum phosphoricum, nadidum, naphthochinonum, natrium diethyloxalaceticum, natrium riboflavinum phosphoricum, nicotinamidum, p-benzochinonum, podophyllum peltatum, pyridoxinum hydrochloricum, sulfur, thiaminum hydrochloricum, trichinoylum, ubidecarenonum, vaccinium myrtillus acidum a-ketoglutaricum, acidum ascorbicum, 13 years 31/12/2018 31/03/2019 acidum cis-aconiticum, acidum citricum, acidum fumaricum, acidum malicum, acidum succinicum, acidum thiocticum, adenosinum triphosphoricum, barium oxalsuccinicum, beta vulgaris rubra, cerium oxalicum, coenzym A, cysteinum, hepar sulfuris, magnesium oroticum dihydricum, manganum phosphoricum, nadidum, natrium diethyloxalaceticum, natrium pyruvicum, natrium riboflavinum phosphoricum, nicotinamidum, pulsatilla pratensis, pyridoxinum hydrochloricum, sulfur, thiaminum hydrochloricum acidum a-ketoglutaricum, acidum fumaricum, 13 years 31/12/2020 31/03/2021 acidum malicum, acidum oroticum monohydricum, acidum thiocticum, avena sativa, calcium carbonicum Hahnemanni, chelidonium majus, cinchona pubescens, colon suis, cyanocobalaminum, cynara scolymus, duodenum suis, hepar suis, histaminum, lycopodium clavatum, natrium diethyloxalaceticum,
Load more

Recommended publications
  • Nootropics: Boost Body and Brain? Report #2445
    NOOTROPICS: BOOST BODY AND BRAIN? REPORT #2445 BACKGROUND: Nootropics were first discovered in 1960s, and were used to help people with motion sickness and then later were tested for memory enhancement. In 1971, the nootropic drug piracetam was studied to help improve memory. Romanian doctor Corneliu Giurgea was the one to coin the term for this drug: nootropics. His idea after testing piracetam was to use a Greek combination of “nous” meaning mind and “trepein” meaning to bend. Therefore the meaning is literally to bend the mind. Since then, studies on this drug have been done all around the world. One test in particular studied neuroprotective benefits with Alzheimer’s patients. More tests were done with analogues of piracetam and were equally upbeat. This is a small fraction of nootropic drugs studied over the past decade. Studies were done first on animals and rats and later after results from toxicity reports, on willing humans. (Source: https://www.purenootropics.net/general-nootropics/history-of-nootropics/) A COGNITIVE EDGE: Many decades of tests have convinced some people of how important the drugs can be for people who want an enhancement in life. These neuro-enhancing drugs are being used more and more in the modern world. Nootropics come in many forms and the main one is caffeine. Caffeine reduces physical fatigue by stimulating the body’s metabolism. The molecules can pass through the blood brain barrier to affect the neurotransmitters that play a role in inhibition. These molecule messengers can produce muscle relaxation, stress reduction, and onset of sleep. Caffeine is great for short–term focus and alertness, but piracetam is shown to work for long-term memory.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Effect of the Roots of Empathy Program on the Use of Psychotropic Medications Among Youth in Manitoba
    The effect of the Roots of Empathy program on the use of psychotropic medications among youth in Manitoba by Lindsey Dahl A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of MASTER OF SCIENCE Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine University of Manitoba Winnipeg Copyright © 2017 by Lindsey Dahl Abstract Background: Psychotropic medications prescriptions to youth have increased. Roots of Empathy (ROE) is a social and emotional learning program that may influence the use of psychotropic medication. Methods: Administrative data was analyzed in a matched sample of children who received ROE during 2002/03 to 2012/13. Kaplan-Meier survival curves and Cox proportional hazard models were used to estimate the association between ROE and psychotropic medication dispensations. Results: Few significant differences were observed. Children who received ROE in kindergarten to grade 3 had a lower adjusted hazard for an anxiolytic dispensation. Children who received ROE in grade 7 to 8 had a higher hazard for an antipsychotic dispensation. Males who received the program had an increased hazard for an antipsychotic dispensation. Conclusion: There was no consistent differences in the likelihood of being dispensed a psychotropic medication between children who received ROE and children who did not in Manitoba. ii Acknowledgments I would like to first thank my thesis advisor Dr. Randy Fransoo of the Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine at the University of Manitoba. Right from our initial meeting, Dr.
    [Show full text]
  • Anatomy and Physiology of Peritoneal Dialysis
    Anatomy and Physiology of Peritoneal Dialysis Isaac Teitelbaum, MD Professor of Medicine Director, Acute & Home Dialysis Programs University of Colorado Hospital Denver, Colorado •1 Outline • Peritoneal cavity as a dialysis system • Models of peritoneal transport • Physiology of peritoneal transport Inverse relationship between solute transport and ultrafiltration • Kinetics of peritoneal transport • Synthesis & Application • Middle Molecules Anatomy of The Peritoneum • The lining of the abdominal cavity • Two layers: parietal - lines the anterior wall and undersurface of the diaphragm - 20% of total SA; blood supply from abdominal wall visceral - covers the abdominal organs - 80% of total SA; blood supply from mesenteric aa and portal vv Gokal R, Textbook of PD, pp. 61-70 •3 Anatomy of The Peritoneum • Size 1.5 – 2 m2; approximates BSA • Highly Vascular • Semi-permeable/bi-directional • “Lymphatic” drainage through diaphragmatic stomata • Continuous with Fallopian Tubes in females Gokal R, Textbook of PD, pp. 61-70 1. The two main properties of the peritoneal membrane are: a. Semi permeable – this allows substances of certain sizes to move from an area of greater concentration to less concentration. b. Bi Directional - substances move in either direction across the membrane. 2. So-called “lymphatic” drainage refers to bulk flow from the peritoneal cavity back to the circulation. This actually occurs across tissues as well as lymphatics. As this is convective flow, dissolved solutes move with the fluid. Thus, fluid reabsorption results in loss of solute clearance as well as loss of fluid removal. 3. It is important to be aware of the continuity of the peritoneal cavity with the Fallopian tubes as retrograde menstruation- which may occur in any woman but goes undetected- will cause bloody dialysate and create concern in the PD patient.
    [Show full text]
  • |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
    |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al.
    [Show full text]
  • Screening of 109 Neuropeptides on Asics Reveals No Direct Agonists
    www.nature.com/scientificreports OPEN Screening of 109 neuropeptides on ASICs reveals no direct agonists and dynorphin A, YFMRFamide and Received: 7 August 2018 Accepted: 14 November 2018 endomorphin-1 as modulators Published: xx xx xxxx Anna Vyvers, Axel Schmidt, Dominik Wiemuth & Stefan Gründer Acid-sensing ion channels (ASICs) belong to the DEG/ENaC gene family. While ASIC1a, ASIC1b and ASIC3 are activated by extracellular protons, ASIC4 and the closely related bile acid-sensitive ion channel (BASIC or ASIC5) are orphan receptors. Neuropeptides are important modulators of ASICs. Moreover, related DEG/ENaCs are directly activated by neuropeptides, rendering neuropeptides interesting ligands of ASICs. Here, we performed an unbiased screen of 109 short neuropeptides (<20 amino acids) on fve homomeric ASICs: ASIC1a, ASIC1b, ASIC3, ASIC4 and BASIC. This screen revealed no direct agonist of any ASIC but three modulators. First, dynorphin A as a modulator of ASIC1a, which increased currents of partially desensitized channels; second, YFMRFamide as a modulator of ASIC1b and ASIC3, which decreased currents of ASIC1b and slowed desensitization of ASIC1b and ASIC3; and, third, endomorphin-1 as a modulator of ASIC3, which also slowed desensitization. With the exception of YFMRFamide, which, however, is not a mammalian neuropeptide, we identifed no new modulator of ASICs. In summary, our screen confrmed some known peptide modulators of ASICs but identifed no new peptide ligands of ASICs, suggesting that most short peptides acting as ligands of ASICs are already known. Acid-sensing ion channels form a small family of proton-gated ion channels that belongs to the degenerin/epi- thelial Na+ channel (DEG/ENaC) gene family1.
    [Show full text]
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
    [Show full text]
  • List of Substances Under PSUR WS Scheme and Other Substances
    ABCDEFGHIJKL List of substances under PSUR Work Sharing scheme and other substances contained in Nationally Authorised Products with DLP synchronised Status July 2013 In brown font: changes made since last publication on 30th June 2013 1 Are PSURs required for Substances under PSUR Submission of Innovator brand products referred Work Sharing scheme PSURs by name (for fixed DLP (year Allocated PRMS / Note on PSUR to in Articles or Others (contained in Active substance name (INN) EU HBD Firm's Name Comments Next DLP (DLP + 90 combination and month) Procedure number cycle 10(1), 10a, 14 and Nationally Authorised days by products only) 16a of Directive Products including default) 2001/83/EC as MRP/DCP) 2 amended? sulbactam No, except if required nationally 19871116 201311 Pfizer AT/H/PSUR/0004/003 201402 Work Sharing by a competent 3 authority idarubicin No, except if required nationally 19891129 201311 Pfizer AT/H/PSUR/0005/003 201402 Work Sharing by a competent 4 authority dexibuprofen No, except if required nationally 20000725 31/08/2014 Gebro Pharma AT/H/PSUR/0009/003 29/11/2014 Work Sharing by a competent 5 authority nicorandil No, except if required nationally 19900209 201302 Merck AT/H/PSUR/0023/002 201305 Work Sharing by a competent 6 authority azelastine Request from MEDA Pharma GmbH & Co.KG to amend the DLP to 31/12/2014. Request agreed by the P- No, except if RMS AT. The substance has required nationally 20/11/1990 201309 Meda been moved to the EURD AT/H/PSUR/0038/001 201312 Work Sharing by a competent list as detailed in the
    [Show full text]
  • Comparison of Clinical Effects Between
    Kanno et al. Renal Replacement Therapy (2020) 6:7 https://doi.org/10.1186/s41100-019-0253-4 REVIEW Open Access Comparison of clinical effects between icodextrin and glucose solutions on outcomes of peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials Atsuhiro Kanno1*, Yasushi Tsujimoto2, Takayuki Fujii3, Emi Fujikura4, Kimio Watanabe5, Hidemichi Yuasa6, Munekazu Ryuzaki7, Yasuhiko Ito8 and Hidetomo Nakamoto9 Abstract Background: Icodextrin enhances peritoneal filtration for patients on peritoneal dialysis (PD). However, clinically important outcomes have not yet been analyzed using authentic, objective statistical methods. The present systematic review aimed to determine the risks and benefits of icodextrin compared with a glucose-based solution with respect to clinically important and patient-centered outcomes. Methods: We systematically investigated only randomized controlled trials (RCTs) by adopting the Cochrane Database of Systematic Review (2014) and searched the CENTRAL, MEDLINE, and EMBASE databases for eligible studies reported in the literature. The quality of the evidence was assessed using the GRADE approach. Results: We finally evaluated important outcomes in 13 RCTs. Icodextrin significantly decreased the number of reported episodes of uncontrolled fluid overload in four RCTs that involved 236 patients (relative risk [RR], 0.31; 95% confidence interval [CI], 0.12 to 0.82; moderate certainty evidence). However, the inclusion of icodextrin for peritoneal ultrafiltration did not significantly differ in six RCTs involving 252 patients (mean difference [MD], 186.76 mL; 95% CI, − 47.08 to 420.59; low certainty evidence). Regarding other clinically important outcomes, all-cause mortality in 10 RCTs involving 1106 patients (RR, 0.75; 95% CI, 0.33 to 1.71; low certainty evidence) and technical survival in five RCTs involving 470 patients (RR, 0.57; 95%CI, 0.29 to 1.12; low certainty evidence) were not significant.
    [Show full text]